Mycophenolate mofetil plus temozolomide for newly diagnosed glioblastoma (early-phase)
A Phase 1 Adaptive Dose Escalation Study of Mycophenolate Mofetil in Combination with Temozolomide for Patients with Newly Diagnosed Glioblastoma
This early-phase trial tests whether adding the drug mycophenolate mofetil to standard temozolomide chemotherapy is safe and tolerable for people newly diagnosed with glioblastoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11187084 on NIH RePORTER |
What this research studies
If you are newly diagnosed with glioblastoma and receiving standard surgery and temozolomide, this project adds mycophenolate mofetil and uses an adaptive dose-escalation plan to find a safe dose. Doctors will monitor side effects closely and may collect blood and tumor-related samples to look for biomarkers linked to how the drugs work. The team is building on lab findings about cancer cell purine metabolism to see whether this combination can reduce treatment resistance. Participation will involve regular clinic visits, scans, and blood tests while dosing is adjusted to balance safety and potential benefit.
Who could benefit from this research
Good fit: Adults with newly diagnosed glioblastoma who are planning to receive temozolomide and meet medical safety criteria would be the ideal candidates.
Not a fit: People with recurrent glioblastoma, those unable to tolerate immunosuppressive medications, or pediatric patients are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the combination could make standard chemotherapy work better and reduce the chance of tumor recurrence.
How similar studies have performed: This approach is largely novel in glioblastoma: supporting lab and preclinical data exist, but human data are limited and this is an early-phase safety-focused effort.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Ahmed, Atique U. — Northwestern University
- Study coordinator: Ahmed, Atique U.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.